Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
about
Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farMolecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsTargeting dormant micrometastases: rationale, evidence to date and clinical implicationsTargeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Organic Nanomaterials and Their Applications in the Treatment of Oral DiseasesCIViC databaseTreatment of Elderly Patients with Squamous Cell Carcinoma of the Head and NeckRisk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckNew developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.Immunotherapy in head and neck cancer: aiming at EXTREME precision.Modulation of influenza vaccine immune responses using an epidermal growth factor receptor kinase inhibitor.Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis.miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer.Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.Squamous Cell Cancers: A Unified Perspective on Biology and GeneticsA genetic view of laryngeal cancer heterogeneityAfatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trialA phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.Introducing Cytology-Based Theranostics in Oral Squamous Cell Carcinoma: A Pilot Program.Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.Investigational drugs for nasopharyngeal carcinoma.Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer.Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.Current Role of Dacomitinib in Head and Neck Cancer.Afatinib in squamous cell carcinoma of the head and neck.Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma
P2860
Q26745776-1DC53ED9-74D6-4315-A4DA-0B59A615F075Q26750719-2982749E-566F-4003-BA95-014B7AC725CCQ26765205-0D8CED51-284A-4B8E-B16F-D682B6930F77Q26765429-E767F1A3-026B-494E-A9F6-B70D42D29265Q26766613-05CDEB44-AA3D-4E00-9E9A-E813555D22FFQ27612411-41E027DA-3A26-4E14-B156-41384D461C01Q28076894-ADA36D71-DDB0-40F4-B4A1-43A7F93D3598Q30248499-50176807-E603-49D2-82A8-27CD5DD1C72BQ33425039-8B2940A4-0AF2-47AC-A48B-DA14AC57327CQ33434648-589BED4B-84FB-440A-988F-BFB66C3B662CQ33591405-BFFC86A2-68AD-48B3-9437-FF8060FC6D93Q33650470-97E0D53A-3BF4-473A-BD0F-36E30D5CE69AQ33704088-C7D8A23F-BAEC-4BDB-85EE-135AB0148E77Q33756244-DFEE41BD-4537-430B-850B-4A92BDFD0BD9Q35905805-D07472A8-50FB-4411-9970-C5E14D539DDCQ36009462-FBE7FF57-32E4-472D-80EE-1FFEFA5AF452Q36132797-B27B5870-03D1-4585-9B93-5A9A38D12050Q36238876-293E88A4-ABF5-41D4-91BE-F67860781E41Q36371601-4EB94A56-3AFB-4A0A-8A31-F632FBA4EF36Q36447729-410EF713-75C8-47F5-AEBD-3186F6A3E645Q36766842-0202526B-C617-4645-83F1-F665A98CBE55Q36909843-02B753DF-3566-421D-BEC1-2EDAA1225212Q36972817-4AEED820-3CFB-4423-8EE9-D95918FF586FQ37123921-1F75013C-B340-49A1-8100-53095C0DA78BQ37284056-D2D48840-22D2-492A-89E1-9458D6D17B7CQ37496660-19DE536B-1672-417F-A016-D3AD23E13A99Q37578362-A8C8A391-B2E4-4ABD-A291-60120D39FA67Q38383481-C30497D8-7A60-4BD3-9617-871AAEFB9949Q38514601-40031F9C-5A9D-4D0C-A4EE-EEB1E48E63ACQ38646686-79A1205E-E1D7-4323-B327-467397D69A59Q38690528-98F3F09E-0CB4-42AE-9958-BA04E9B78126Q38723429-683E488A-340A-4D99-ADAD-CEEA1CD13DD7Q38724189-1E827A57-2608-45A1-AC54-81F203BE16C8Q38806115-225DE14C-74A1-44D4-9CF2-036E66D99FBDQ38829891-15AE8765-8997-41A8-874B-61158A22FDB1Q38838071-377AB237-99E6-42DD-9669-27263054814CQ38851114-6444686C-4C1B-4F00-808C-1D4BBE6F0674Q38854643-61EB5D80-F925-4AF1-900B-10B2BE852C06Q38892486-A9E81C53-ABCB-4BBB-AB04-0C45ECEFBE40Q38935842-799A707C-86B9-427F-9001-E32EDBF7A3E1
P2860
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Afatinib versus methotrexate a ...... abel, randomised phase 3 trial
@ast
Afatinib versus methotrexate a ...... abel, randomised phase 3 trial
@en
Afatinib versus methotrexate a ...... abel, randomised phase 3 trial
@nl
type
label
Afatinib versus methotrexate a ...... abel, randomised phase 3 trial
@ast
Afatinib versus methotrexate a ...... abel, randomised phase 3 trial
@en
Afatinib versus methotrexate a ...... abel, randomised phase 3 trial
@nl
prefLabel
Afatinib versus methotrexate a ...... abel, randomised phase 3 trial
@ast
Afatinib versus methotrexate a ...... abel, randomised phase 3 trial
@en
Afatinib versus methotrexate a ...... abel, randomised phase 3 trial
@nl
P2093
P921
P3181
P1433
P1476
Afatinib versus methotrexate a ...... bel, randomised phase 3 trial.
@en
P2093
Didier Cupissol
Eva Ehrnrooth
Ezra E W Cohen
Francesco Caponigro
Gilberto de Castro
Jan B Vermorken
Jean-Pascal H Machiels
Joseph M Del Campo
Joël Guigay
Juan José Grau
P304
P3181
P356
10.1016/S1470-2045(15)70124-5
P50
P577
2015-05-01T00:00:00Z